CS Diagnostics Corp. Announces U.S. Launch of MEDUSA
CS Diagnostics Corp. (OTCQB: CSDX) has announced the U.S. launch of MEDUSA, a next-generation smart disinfectant product, alongside CS Protect-Hydrogel. The product offers protection for up to 10 days on touched surfaces and comes in two formulations: an alcohol-free version for high-traffic environments and an alcohol-based version for medical settings.
MEDUSA has already received approval in the EU and UAE, with U.S. approval pending. The company is in advanced negotiations for a sponsorship deal with a major European football club. CS Diagnostics aims to achieve $80 million in revenue by 2025, targeting both B2B and B2C markets, with plans to expand to 15 markets within three years and generate $460 million in revenue. The company projects capturing 10% of the global disinfectant market, estimated to be worth $8.37 billion in 2025.
CS Diagnostics Corp. (OTCQB: CSDX) ha annunciato il lancio negli Stati Uniti di MEDUSA, un prodotto disinfettante intelligente di nuova generazione, insieme a CS Protect-Hydrogel. Il prodotto offre protezione fino a 10 giorni sulle superfici toccate e viene in due formulazioni: una versione senza alcol per ambienti ad alto transito e una versione a base di alcol per contesti medici.
MEDUSA ha già ricevuto approvazione nell'UE e negli Emirati Arabi Uniti, mentre l'approvazione negli Stati Uniti è in attesa. L'azienda è in trattative avanzate per un accordo di sponsorizzazione con un importante club calcistico europeo. CS Diagnostics mira a raggiungere 80 milioni di dollari di fatturato entro il 2025, targetando sia i mercati B2B che B2C, con piani di espansione in 15 mercati nei prossimi tre anni e di generare 460 milioni di dollari di fatturato. L'azienda prevede di acquisire il 10% del mercato globale dei disinfettanti, stimato in 8,37 miliardi di dollari nel 2025.
CS Diagnostics Corp. (OTCQB: CSDX) ha anunciado el lanzamiento en EE. UU. de MEDUSA, un producto desinfectante inteligente de nueva generación, junto con CS Protect-Hydrogel. El producto ofrece protección de hasta 10 días en superficies tocadas y viene en dos formulaciones: una versión sin alcohol para entornos de alto tráfico y una versión a base de alcohol para entornos médicos.
MEDUSA ya ha recibido aprobación en la UE y los Emiratos Árabes Unidos, mientras que la aprobación en EE. UU. está pendiente. La empresa está en negociaciones avanzadas para un acuerdo de patrocinio con un importante club de fútbol europeo. CS Diagnostics tiene como objetivo alcanzar 80 millones de dólares en ingresos para 2025, apuntando a mercados tanto B2B como B2C, con planes de expandirse a 15 mercados en tres años y generar 460 millones de dólares en ingresos. La empresa proyecta capturar el 10% del mercado mundial de desinfectantes, estimado en 8.37 mil millones de dólares para 2025.
CS Diagnostics Corp. (OTCQB: CSDX)는 MEDUSA라는 차세대 스마트 소독제 제품의 미국 출시를 발표했으며, CS Protect-Hydrogel과 함께합니다. 이 제품은 접촉한 표면에서 최대 10일 동안 보호를 제공하며, 두 가지 제형으로 제공됩니다: 고밀도의 환경에 적합한 무알콜 버전과 의료 환경에 적합한 알콜 기반 버전입니다.
MEDUSA는 이미 EU와 UAE에서 승인을 받았으며, 미국 승인은 대기 중입니다. 회사는 주요 유럽 축구 클럽과의 스폰서십 계약을 위한 고급 협상 중에 있습니다. CS Diagnostics는 2025년까지 8천만 달러의 수익을 목표로 하고 있으며, B2B 및 B2C 시장 모두를 타겟으로 하고 있으며, 향후 3년 내에 15개 시장으로 확장하고 4억 6천만 달러의 수익을 창출할 계획입니다. 이 회사는 2025년까지 83억 7천만 달러로 추정되는 세계 소독제 시장의 10%를 차지할 것으로 예상하고 있습니다.
CS Diagnostics Corp. (OTCQB: CSDX) a annoncé le lancement aux États-Unis de MEDUSA, un produit désinfectant intelligent de nouvelle génération, aux côtés de CS Protect-Hydrogel. Le produit offre une protection pouvant aller jusqu'à 10 jours sur les surfaces touchées et est disponible en deux formulations : une version sans alcool pour les environnements à fort trafic et une version à base d'alcool pour les milieux médicaux.
MEDUSA a déjà reçu l'approbation de l'UE et des Émirats Arabes Unis, tandis que l'approbation américaine est en attente. L'entreprise est en négociations avancées pour un accord de sponsoring avec un grand club de football européen. CS Diagnostics vise à réaliser 80 millions de dollars de revenus d'ici 2025, ciblant à la fois les marchés B2B et B2C, avec des plans d'expansion sur 15 marchés dans les trois ans et de générer 460 millions de dollars de revenus. L'entreprise projette de capturer 10 % du marché mondial des désinfectants, évalué à 8,37 milliards de dollars en 2025.
CS Diagnostics Corp. (OTCQB: CSDX) hat die Einführung von MEDUSA, einem smarten Desinfektionsmittel der nächsten Generation, in den USA bekannt gegeben, zusammen mit CS Protect-Hydrogel. Das Produkt bietet bis zu 10 Tage Schutz auf berührten Oberflächen und gibt es in zwei Formulierungen: einer alkoholfreien Version für stark frequentierte Umgebungen und einer alkoholhaltigen Version für medizinische Einrichtungen.
MEDUSA hat bereits Genehmigungen in der EU und den VAE erhalten, während die Genehmigung in den USA noch aussteht. Das Unternehmen befindet sich in fortgeschrittenen Verhandlungen über einen Sponsorenvertrag mit einem großen europäischen Fußballverein. CS Diagnostics strebt an, bis 2025 einen Umsatz von 80 Millionen Dollar zu erzielen, und zielt sowohl auf B2B- als auch auf B2C-Märkte ab, mit Plänen, innerhalb von drei Jahren auf 15 Märkte zu expandieren und 460 Millionen Dollar Umsatz zu generieren. Das Unternehmen rechnet damit, 10 % des weltweiten Desinfektionsmittelmarktes, der bis 2025 auf 8,37 Milliarden Dollar geschätzt wird, zu erobern.
- Product offers extended 10-day protection on surfaces
- Already approved in EU and UAE markets
- Projected revenue of $80 million by 2025
- Targeted revenue of $460 million within three years
- Aims to capture 10% of $8.37 billion global disinfectant market
- U.S. regulatory approval still pending
- Revenue projections heavily dependent on future market penetration
- Significant competition in established disinfectant market
Innovative smart disinfectant formula suitable for a wide range of environments
In sponsorship talks with leading European football club
NEUSS,
MEDUSA has been approved in key global regions including the EU and the
The core, alcohol-free formula is safe and effective for use in high-traffic environments, for example hotels, schools, public spaces, and sports venues. Additionally, an alcohol-based version is specifically formulated for medical settings such as clinics and hospitals. Backed by advanced material science, MEDUSA’s protection and efficacy make it a leading solution against pathogens. This product is designed for both B2B and B2C markets, offering businesses and individuals reliable, safe disinfecting solutions.
Thomas Fahrhoefer, President of the Board at CS Diagnostics Corp., added:
“The launch of MEDUSA in the
CS Diagnostics Corp. is also thrilled to be in advanced negotiations for a sponsorship deal with one of Europe’s most iconic football clubs. As a global leader in sports and entertainment, a partnership with this club would bring MEDUSA to the forefront of both the sports industry and public spaces worldwide. The market will be updated as developments unfold.
The global disinfectant market is valued at an estimated
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
“By launching MEDUSA, we aim to achieve
Looking toward the future, CS Diagnostics Corp. is positioning itself for long-term growth with breakthrough innovations. As a listed entity on OTCQB, CS Diagnostics Corp. provides U.S. investors with access to a high-growth opportunity, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Actual results achieved may vary from the information provided herein because of numerous known and unknown risks and uncertainties and other factors.
Watch the video: https://youtube.com/shorts/xUBsn_HKjdk?feature=share
For further information please visit:
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121689973/en/
Mohammad Essayed
mohammad.essayed@csdcorp.us
Source: CS Diagnostics Corp.
FAQ
What is the expected revenue target for CSDX's MEDUSA product by 2025?
How long does MEDUSA's surface protection last?
In which markets has MEDUSA received regulatory approval?
What are the two formulations of MEDUSA offered by CSDX?
What is CSDX's target market share in the global disinfectant market?
How many markets does CSDX plan to enter with MEDUSA within three years?
